NIKKEI 225
38,913.48 +296.38 (+0.77%) HANG SENG
18,946.51 -249.09 (-1.30%) CRUDE OIL
77.16 -0.41 (-0.53%) GOLD FUTURES
2,372.90 -20.00 (-0.84%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,445.17 -517.48 (-0.94%)
Apellis Pharmaceuticals, Inc. (APLS)
After hours:
| Previous close | 42.56 |
| Open | 42.63 |
| Bid | 43.58 x 100 |
| Ask | 43.66 x 100 |
| Day's range | 42.05 - 43.99 |
| 52-week range | 19.83 - 94.75 |
| Volume | |
| Avg. volume | 1,473,746 |
| Market cap | 5.292B |
| Beta (5Y monthly) | 0.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.51 |
| Earnings date | 29 Jul 2024 - 02 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 80.13 |
GlobeNewswireApellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceeds used to buy out existing SFJ Pharmaceuticals development liability Significantly improves liquidity profile by eliminating $366 million in SFJ payments through 2027 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that it has entered into a non-dilutive, senior secured credit facility with Sixth Street, a le
Simply Wall St.Analysts Are Updating Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates After Its First-Quarter Results
There's been a notable change in appetite for Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shares in the week since...
Insider MonkeyApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript May 7, 2024 Apellis Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.54 EPS, expectations were $-0.54. Apellis Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good […]
